Bio-Thera Solutions (SHA: 688177), a Guangzhou-based biopharmaceutical company, has announced a licensing and commercialization agreement with Macter International Ltd., a company based in Pakistan. Under the terms of the agreement, Bio-Thera will transfer Avzivi (bevacizumab), a biosimilar version of Roche’s Avastin, to Macter. Macter will gain exclusive distribution and marketing rights for the product in Pakistan and Afghanistan, with Bio-Thera taking on the responsibility for supply. The financial details of the agreement have not been disclosed.
Bevacizumab, a human anti-VEGF monoclonal antibody (mAb), was first approved in China in February 2010 and has been included on the National Reimbursement Drug List (NRDL) since 2017. The drug’s market-approved indications encompass a range of cancers, including non-small cell lung cancer (NSCLC), metastatic colorectal cancer (mCRC), glioblastoma (GBM), renal cell carcinoma, cervical cancer, and ovarian cancer.- Flcube.com
